What is Rapport Therapeutics, Inc.'s investing cash flow?

Rapport Therapeutics, Inc. (RAPP) reported investing cash flow of $37.94M in Q1 2026.

How has Rapport Therapeutics, Inc.'s investing cash flow changed year-over-year?

Rapport Therapeutics, Inc.'s investing cash flow increased by 80.4% year-over-year, from $21.03M to $37.94M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Rapport Therapeutics, Inc. RAPP Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers SquibbBMY

-$131M+73.7%

Supernus PharmaceuticalsSUPN

-$19.22M-151%

Xenon PharmaceuticalsXENE

-$407.28M-1,280%

Praxis Precision Medicines, Inc.PRAX

-$344.28M-574%

BiohavenBHVN

$15.21M-90.8%

Septerna, Inc.SEPN

-$23.82M-389%

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.86B+309%

Enterprise value$1.79B+352%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s investing cash flow?: Rapport Therapeutics, Inc. (RAPP) reported investing cash flow of $37.94M in Q1 2026.
How has Rapport Therapeutics, Inc.'s investing cash flow changed year-over-year?: Rapport Therapeutics, Inc.'s investing cash flow increased by 80.4% year-over-year, from $21.03M to $37.94M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.